

Publication Agreement

This is a publication agreement¹ (“this agreement”) regarding a written manuscript currently entitled

A non-conformity approach towards post-prostatectomy metastasis estimation using a multicenter prostate cancer database

(“the article”) to be published in PMLR (“the proceedings”). The parties to this Agreement are:

JANSSEN PHARMACEUTICA NV

(name of corresponding company owner of the article who signs on behalf of any other authors, collectively “the company”) and PMLR, (“the publisher”).

1. By signing this form, the company warrants that the company is signing on behalf of all authors of the article, and that the company has the authority to act as their agent for the purpose of entering into this agreement.
2. The company hereby grants a Creative Commons copyright license in the article to the general public, in particular a Creative Commons Attribution 4.0 Inter-national License, which is incorporated herein by reference and is further specified at <http://creativecommons.org/licenses/by/4.0/legalcode> (human readable summary at <http://creativecommons.org/licenses/by/4.0>).
3. The company agrees to require that a citation to the original publication of the article in the proceedings as well as a hyperlink to the PMLR web site linking to the original paper be included in any attribution statement satisfying the attribution requirement of the Creative Commons license of paragraph 2.
4. The company retains ownership of all rights under copyright in all versions of the article, and all rights not expressly granted in this agreement.
5. To the extent that any edits made by the publisher to make the article suitable for publication in the proceedings amount to copyrightable works of authorship, the publisher hereby assigns all right, title, and interest in such edits to the company. The publisher agrees to verify with the company any such edits that are substantive. The company agrees that the license of paragraph 2 covers such edits.

¹The language of this publication agreement is based on Stuart Shieber’s model open-access journal publication agreement, version 1.2, available at <http://bit.ly/1m9UsNt>.

6. The company further warrants that:
1. The article is original, has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication.
 2. The company has a complete and unencumbered right to make the grants the company makes.
 3. The article does not libel anyone, invade anyone's copyright or other-wise violate any statutory or common law right of anyone, and that the company has made all reasonable efforts to ensure the accuracy of any factual information contained in the article. The company agrees to indemnify the publisher against any claim or action alleging facts which, if true, constitute a breach of any of the foregoing warranties or other provisions of this agreement, as well as against any related damages, losses, liabilities, and expenses incurred by the publisher.
7. This is the entire agreement between the company and the publisher, and it may be modified only in writing. It will be governed by the laws of the Commonwealth of Massachusetts. It will bind and benefit our respective assigns and successors in interest, including your heirs. It will terminate if the publisher does not publish, in any medium, the article within one year of the date of the company's signature.

I HAVE READ AND AGREE FULLY WITH THE TERMS OF THIS AGREEMENT.

JANSSEN PHARMACEUTICA NV

-Signed by: Bert Hartog

-Title: Senior Director Janssen Clinical Innovation

- Date: August 11th, 2021

